Detalhe da pesquisa
1.
GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers.
Vaccine
; 41(42): 6261-6271, 2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37666695
2.
Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya.
mSphere
; 7(3): e0102021, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35611657
3.
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
EBioMedicine
; 66: 103310, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862589
4.
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
EBioMedicine
; 66: 103308, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33813141
5.
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
mSphere
; 5(5)2020 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32968012
6.
A High-throughput Shigella-specific Bactericidal Assay.
J Vis Exp
; (144)2019 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30882773
7.
Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay.
mSphere
; 3(3)2018 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898979
8.
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
Clin Vaccine Immunol
; 23(12): 908-917, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27581434